Archive for June, 2006
Next Entries »FDA Approves Wellbutrin XL(R) (bupropion HCl Extended-release Tablets) For The Prevention Of Seasonal Major Depressive Episodes
Tuesday, June 13th, 2006The U.S. Food andDrug Administration (FDA) has approved Wellbutrin XL(R) for the preventionof seasonal major depressive episodes in patients with a diagnosis ofseasonal affective disorder (SAD), a condition affecting about 6 percent ofAmerican adults. Wellbutrin XL is the first and only medication approved toprevent seasonal major depressive episodes. [click link for full article]
FDA Approves Wellbutrin XL(R) (bupropion HCl Extended-release Tablets) For The Prevention Of Seasonal Major Depressive Episodes
Tuesday, June 13th, 2006The U.S. Food andDrug Administration (FDA) has approved Wellbutrin XL(R) for the preventionof seasonal major depressive episodes in patients with a diagnosis ofseasonal affective disorder (SAD), a condition affecting about 6 percent ofAmerican adults. Wellbutrin XL is the first and only medication approved toprevent seasonal major depressive episodes. [click link for full article]
European Medicines Agency Adopts Positive Opinion For Use Of Prozac For Children And Adolescents Suffering From Depression
Thursday, June 8th, 2006The European Medicines Agency has recommended to extend the indication for Prozac (fluoxetine) and associated names to include the treatment of children of 8 years of age or older who suffer from moderate to severe depression and who do not respond to psychological therapy. [click link for full article]
Seroquel Study Gives Hope For Beating Depression In Bipolar Disorder
Sunday, June 4th, 2006Keeping the manic-depressive illness Bipolar Disorder under control may become simpler in future if psychiatrists implement new research findings from the BOLDER II study presented during the American Psychiatry Association’s 159th annual meeting 20-25 May 2006. Currently patients have to take three or four different drugs to control symptoms of mania and depression, keep moods on an even keel and to try and prevent relapse. [click link for full article]
Efexor (Venlafaxine) Questions And Answers, MHRA, UK
Sunday, June 4th, 20061. What is venlafaxine?Venlafaxine is an anti-depressant, belonging to a class of drugs known as serotonin noradrenaline reuptake inhibitors. The conventional release form of venlafaxine (Efexor tablets) has been licensed for the treatment of depression since 1994 and the modified release form, Efexor XL (capsules), was introduced in 1997. The ‘Efexor’ brand is for the treatment of major depressive disorder (including depression accompanied by anxiety). [click link for full article]
Updated Product Information For Efexor, MHRA, UK
Sunday, June 4th, 2006The Medicines and Healthcare products Regulatory Agency (MHRA) has concluded its review into all the latest safety evidence relating to Efexor (venlafaxine), an anti-depressant belonging to a class of medicines known as serotonin and noradrenaline reuptake inhibitors (SNRIs) The review particularly looked at the risks associated with overdose. Updated prescribing advice is designed to minimise the risks of side effects, especially in overdose. [click link for full article]
Next Entries »